BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20413369)

  • 1. Angiogenic fast-growing melanomas and their micrometastases.
    Quatresooz P; Pierard-Franchimont C; Paquet P; Pierard GE
    Eur J Dermatol; 2010; 20(3):302-7. PubMed ID: 20413369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
    Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
    Melanoma Res; 2007 Dec; 17(6):393-9. PubMed ID: 17992123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients.
    Glumac N; Hocevar M; Zadnik V; Snoj M
    J Surg Oncol; 2008 Jul; 98(1):46-8. PubMed ID: 18452214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor biology of melanoma nodal metastases.
    Miliotes G; Albertini J; Berman C; Heller R; Messina J; Glass F; Cruse W; Rapaport D; Puleo C; Fenske N; Petsoglou C; Deconti R; Lyman G; Reintgen D
    Am Surg; 1996 Jan; 62(1):81-8. PubMed ID: 8540654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural course of cutaneous melanoma.
    Leiter U; Meier F; Schittek B; Garbe C
    J Surg Oncol; 2004 Jul; 86(4):172-8. PubMed ID: 15221923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression.
    Gorski DH; Leal AD; Goydos JS
    J Am Coll Surg; 2003 Sep; 197(3):408-18. PubMed ID: 12946796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
    Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
    Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.
    Page AJ; Carlson GW; Delman KA; Murray D; Hestley A; Cohen C
    Am Surg; 2007 Jul; 73(7):674-8; discussion 678-9. PubMed ID: 17674939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anatomo-pathologic study of sentinel lymph nodes in melanoma. Analysis of 200 cases].
    Riccioni L; Morigi F; Naldi S; Polverelli M; Morelli R; Fiscelli O; Landi G; Giangaspero F
    Pathologica; 1999 Aug; 91(4):242-8. PubMed ID: 10630072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
    Keijzer R; Bril H; van der Loo EM; de Graaf PW
    Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel node identification by scintigraphic methods in cutaneous melanoma.
    Dias Moreira R; Altino de Almeida S; Maliska Guimarães CM; Resende JF; Gutfilen B; Barbosa da Fonseca LM
    J Exp Clin Cancer Res; 2005 Jun; 24(2):181-5. PubMed ID: 16110749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermal vascularity in lentigo maligna.
    Trotter MJ; Tron VA
    J Pathol; 1994 Aug; 173(4):341-5. PubMed ID: 7525908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node.
    Pearl RA; Pacifico MD; Richman PI; Stott DJ; Wilson GD; Grobbelaar AO
    J Exp Clin Cancer Res; 2007 Mar; 26(1):109-15. PubMed ID: 17550139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappa B in the vascular progression of melanoma.
    Kashani-Sabet M; Shaikh L; Miller JR; Nosrati M; Ferreira CM; Debs RJ; Sagebiel RW
    J Clin Oncol; 2004 Feb; 22(4):617-23. PubMed ID: 14966085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reevaluation of the locoregional recurrence rate in melanoma patients with a positive sentinel node compared to patients with palpable nodal involvement.
    Veenstra HJ; van der Ploeg IM; Wouters MW; Kroon BB; Nieweg OE
    Ann Surg Oncol; 2010 Feb; 17(2):521-6. PubMed ID: 19898903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic dissemination of B16 melanoma: pattern and sequence of metastasis.
    Alterman AL; Fornabaio DM; Stackpole CW
    J Natl Cancer Inst; 1985 Oct; 75(4):691-702. PubMed ID: 3862901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The vascularity of primary cutaneous melanoma.
    Fallowfield ME; Cook MG
    J Pathol; 1991 Jul; 164(3):241-4. PubMed ID: 1890549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
    Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
    Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel node in management of malignant melanoma.
    Al-Hiari AA; Al-Kaylani H
    Saudi Med J; 2002 Dec; 23(12):1462-5. PubMed ID: 12518192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.
    Wobser M; Siedel C; Schrama D; Bröcker EB; Becker JC; Vetter-Kauczok CS
    Arch Dermatol Res; 2006 Feb; 297(8):352-7. PubMed ID: 16395613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.